LFG
CLDX icon

Larson Financial Group’s Celldex Therapeutics CLDX Stock Holding History

Larson Financial Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.72K Sell
100
-13
-12% -$420 ﹤0.01% 2888
2026
Q1 		$3.58K Sell
113
-42
-27% -$1.15K ﹤0.01% 2756
2025
Q4 		$4.21K Buy
155
+82
+112% +$2.16K ﹤0.01% 2524
2025
Q3 		$1.89K Buy
+73
New +$1.69K ﹤0.01% 2732

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's CLDX Position: Q2 2026 in Review

Larson Financial Group reduced its Celldex Therapeutics (CLDX) stake by 12% in Q2 2026, selling an estimated $420 and leaving 100 shares worth $3.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2888.

Larson Financial Group first reported a position in CLDX in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.21K in Q4 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Larson Financial Group held 100 shares of Celldex Therapeutics worth $3.72K as of Q2 2026.
  • Larson Financial Group sold 13 Celldex Therapeutics shares in Q2 2026, an estimated $420.
  • Celldex Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2888 holding.
  • Larson Financial Group first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Celldex Therapeutics position peaked at $4.21K in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.